



Figure S1: Principal Component Analysis (PCA) of the metabolome following a 12-week HIIT or MICT in obese older adults. PCA plots performed following the overall 12-week HIIT and MICT interventions together (A); on the delta changes following the 12-week HIIT and MICT interventions (B) following the 12-week HIIT intervention alone (C), following the 12-week MICT intervention alone (D). Individuals refers to participants; Pre = before the 12-week intervention; Post = after the 12-week

Table S1: Effect of a 12-week High-Intensity Interval Training (HIIT) and Moderate-Intensity Continuous Training (MICT) on functional capacities and skeletal muscle function parameters in obese older adults.

Parameters	HIIT (n = 26)		MICT (n = 12)		p-value	
	Pre	Post	Pre	Post	Time effect	Time×Group effect
Functional capacities						
6 min walking test (m)	548.61 ± 80.75	617.81 ± 93.05 ***	534.08 ± 90.15	553.17 ± 75.81	< 0.0001	0.02
Step test (n)	28.76 ± 4.35	33.04 ± 5.33 ***	24.08 ± 7.14	25.25 ± 5.54	< 0.0001	0.005
4 m walk test normal (m/s)	1.37 ± 0.16	1.47 ± 0.15 ***	1.24 ± 0.18	1.34 ± 0.22 #	< 0.0001	0.98
4 m walk test fast (m/s)	1.93 ± 0.22	2.07 ± 0.25	1.80 ± 0.33	2.01 ± 0.73	0.02	0.60
Unipodal Balance Test (s/60s)	24.73 ± 16.31	37.17 ± 20.42 ***	32.55 ± 21.94	40.01 ± 25.93	0.0002	0.39
Chair test (s)	20.19 ± 5.33	16.19 ± 4.15 ***	23.91 ± 6.19	22.37 ± 4.71	0.0001	0.13
Timed Up and Go test (s)	10.20 ± 1.35	9.13 ± 1.12 #	10.91 ± 2.21	9.73 ± 2.89 #	0.0004	0.86
Skeletal muscle function						
Handgrip strength (kg)	34.01 ± 12.58	33.98 ± 11.07	33.28 ± 13.75	25.54 ± 16.95 #	0.23	0.09
Handgrip strength/BW	0.41 ± 0.12	0.41 ± 0.10	0.42 ± 0.14	0.39 ± 0.14	0.73	0.49
Handgrip strength/ALM	6.72 ± 3.36	6.17 ± 0.84	6.27 ± 1.18	6.14 ± 1.58	0.55	0.55
Quadriceps strength (N)	407.11 ± 191.90	386.55 ± 157.29	482.03 ± 185.60	499.16 ± 197.30	0.65	0.07
Quadriceps/BW	4.96 ± 1.97	4.77 ± 1.47	5.99 ± 1.78	6.18 ± 1.90	0.45	0.09
Quadriceps/LLM	15.82 ± 11.16	13.95 ± 7.93 #	27.84 ± 7.08	29.27 ± 7.61	0.44	0.02
Lower limb power (W)	162.08 ± 77.76	185.35 ± 77.70	120.00 ± 66.13	176.42 ± 77.81	0.0001	0.05

Data are presented as: mean ± SD. HIIT = high-intensity interval training; MICT = moderate-intensity continuous training; Pre = before the 12-week intervention; Post = after the 12-week intervention; BW = body weight; ALM = arms lean mass; LLM = legs lean mass; Quad = quadriceps. Time effect and Time×Group effects were analyzed using two-way repeated measures ANOVA. # p < 0.05, ## p < 0.01, ### p < 0.001 = Significant intra-group differences between pre and post intervention using two-ways repeated measures ANOVA followed by post-hoc analyses done with simultaneous tests for general linear hypotheses.

Table S2: Effect of a 12-week High-Intensity Interval Training (HIIT) and Moderate-Intensity Continuous Training (MICT) on body composition parameters in obese older adults.

Parameters	HIIT (n = 26)		MICT (n = 12)		p-value	
	Pre	Post	Pre	Post	Time effect	Time×Group effect
Anthropometry						
Body Weight (kg)	82.11 ± 14.39	81.98 ± 14.22	79.86 ± 16.99	80.52 ± 16.93	0.82	0.49
BMI (kg/m ²)	30.28 ± 5.38	30.24 ± 5.36	29.09 ± 5.85	29.34 ± 5.73	0.81	0.47
Fat and lean mass (DXA)						
Total lean mass (kg)	47.65 ± 9.33	48.36 ± 9.72	50.25 ± 12.92	47.89 ± 12.98	0.06	0.41
Arms lean mass (kg)	5.54 ± 1.75	5.60 ± 1.67	5.27 ± 1.76	5.24 ± 1.80	0.64	0.95
Legs lean mass (kg)	16.88 ± 3.47	17.21 ± 3.64 [#]	17.02 ± 4.69	16.86 ± 4.38	0.11	0.04
Total fat mass (%)	37.75 ± 7.93	37.27 ± 7.67	37.34 ± 7.22	37.02 ± 7.04	0.10	0.76
Arms fat mass (%)	35.94 ± 10.76	35.14 ± 10.33	32.47 ± 10.38	34.12 ± 10.67 [#]	0.97	0.01
Legs fat mass (%)	35.79 ± 11.11	35.11 ± 11.01	34.81 ± 11.08	33.92 ± 10.61	0.02	0.77
Android fat mass (%)	47.07 ± 7.45	46.65 ± 7.55	47.47 ± 5.90	47.54 ± 5.66	0.47	0.54
Gynoid fat mass (%)	39.88 ± 10.48	39.59 ± 10.30	38.75 ± 11.05	38.80 ± 10.77	0.54	0.59
Muscle composition (pQCT)						
Total muscle area (cm ²)	103.66 ± 29.40	102.53 ± 32.17	104.22 ± 29.82	100.64 ± 22.77	0.25	0.41
Total fat area (cm ²)	91.65 ± 52.16	86.72 ± 48.20	76.69 ± 47.61	74.80 ± 47.46	0.23	0.66
Subcutaneous fat area (cm ²)	86.59 ± 51.85	81.90 ± 47.46	72.16 ± 47.38	70.02 ± 47.24	0.25	0.73
Intramuscular fat area (cm ²)	5.05 ± 2.31	4.83 ± 2.35	4.65 ± 2.54	4.36 ± 1.89	0.65	0.95

Data are presented as: mean ± SD. HIIT = high-intensity interval training; MICT = moderate-intensity continuous training; Pre = before the 12-week intervention; Post = after the 12-week intervention; DXA = dual-energy X-ray absorptiometry; pQCT = peripheral quantitative computed tomography; BMI = body mass index. Time effect and Time×Group effect were analyzed using two-way repeated measures ANOVA. [#] p < 0.05 = Significant intra-group differences between pre and post intervention using two-ways repeated measures ANOVA followed by post-hoc analyses done with simultaneous tests for general linear hypotheses.

Table S3: Effect of a 12-week High–Intensity Interval Training (HIIT) and Moderate–Intensity Continuous Training (MICT) on biological parameters in obese older adults.

Parameters	HIIT (n = 26)		MICT (n = 12)		p-value	
	Pre	Post	Pre	Post	Time effect	Time×Group effect
Biological parameters						
Adiponectin ($\mu\text{g.ml}^{-1}$)	14.51 ± 7.98	14.24 ± 8.04	12.03 ± 3.66	12.33 ± 4.80	0.87	0.61
Leptin (ng.ml^{-1})	22.72 ± 18.82	26.23 ± 21.41	24.27 ± 21.90	23.35 ± 18.54	0.31	0.31
Adiponectin/leptin	0.85 ± 0.85	1.21 ± 1.60	1.21 ± 1.60	1.00 ± 1.04	0.29	0.59
Free fatty acids (mmol.l^{-1})	0.52 ± 0.15	0.45 ± 0.18	0.53 ± 0.19	0.54 ± 0.21	0.19	0.27
Total cholesterol (mmmol.l^{-1})	4.97 ± 1.12	5.00 ± 1.07	4.77 ± 0.78	4.93 ± 0.74	0.56	0.63
HDL (mmol.l^{-1})	1.43 ± 0.37	1.46 ± 0.32	1.32 ± 0.30	1.35 ± 0.35	0.08	0.90
LDL (mmol.l^{-1})	2.85 ± 0.92	2.92 ± 0.89	2.73 ± 0.71	2.87 ± 0.61	0.37	0.79
Triglycerides (mmol)	1.53 ± 0.71	1.35 ± 0.68	1.59 ± 0.55	1.54 ± 0.69	0.09	0.48
Ferritin ($\mu\text{g.l}^{-1}$)	138.33 ± 91.43	122.81 ± 94.46 [#]	93.65 ± 48.65	82.67 ± 43.54	0.01	0.68
IGF1 ($\mu\text{g.ml}^{-1}$)	0.08 ± 0.02	0.09 ± 0.02	0.09 ± 0.02	0.09 ± 0.03	0.16	0.77
IGFBP3 ($\mu\text{g.ml}^{-1}$)	1.78 ± 0.39	1.87 ± 0.34	1.73 ± 0.25	1.70 ± 0.27	0.22	0.16
IGF1/IGFBP3	0.05 ± 0.01	0.05 ± 0.01	0.05 ± 0.01	0.05 ± 0.01	0.45	0.23
Glucose (mmol.l^{-1})	5.99 ± 1.28	6.04 ± 1.46	5.70 ± 0.47	5.70 ± 0.80	0.72	0.81
Insulin (pmol)	49.06 ± 23.57	49.03 ± 29.36	55.10 ± 35.51	46.41 ± 26.04	0.29	0.13
QUICKI	0.42 ± 0.05	0.43 ± 0.05	0.42 ± 0.04	0.43 ± 0.04	0.14	0.64
HOMA–IR (M.U)	2.19 ± 1.19	2.21 ± 1.43	2.35 ± 1.57	1.94 ± 1.05	0.37	0.16

Data are presented as: mean ± SD. HIIT = High–Intensity Interval Training; MICT = moderate–intensity continuous training; Pre = before the 12–week intervention; Post = after the 12–week intervention; HDL = high–density lipoprotein; LDL = low–density lipoprotein; IGF–1 = insulin–like growth factor–1; IGFBP–3 = insulin–like growth factor binding protein–3; QUICKI = quantitative insulin–sensitivity check index; HOMA = homeostatic model assessment for insulin resistance; M.U = mass unit. Time effect and Time×Group effect were analyzed using two–way repeated measures ANOVA. [#] $p < 0.05$ = Significant intra–group differences between pre and post intervention using two–ways repeated measures ANOVA followed by post–hoc analyses done with simultaneous tests for general linear hypotheses.

Table S4-a: False Discovery Rate Analysis (FDR) on the 50 significant metabolites obtained following a 12-week High-Intensity Interval Training (HIIT) or Moderate-Intensity Continuous Training (MICT) in obese older adults.

Metabolites	ANOVA		FDR (BH)	
	Time effect	Time×Training effect	Time effect	Time×Training effect
TCA cycle				
2-oxoglutaric acid	0.0002**	0.13	0.03	0.57
3-methylhistidine	0.006**	0.79	0.35	0.96
Aspartic acid	0.12	0.005**	0.63	0.17
Fumaric acid	0.001**	0.71	0.09	0.94
Pyruvic acid and Oxaloacetic acid	0.03*	0.56	0.56	0.89
Aspartate/Malate	0.13	0.003**	0.65	0.15
Carbohydrate metabolism				
Acetic acid	0.04*	0.32	0.56	0.17
Glyceric acid	<0.0001***	0.08	0.03	0.17
Ribitol	0.75	0.04*	0.51	0.51
Xylitol	0.02*	0.004**	0.15	0.15
Xylose	0.31	0.008**	0.73	0.25
Amino acid metabolism				
2-amino adipic acid	0.03*	0.08	0.52	0.52
2-hydroxybutyric acid	0.12	0.04*	0.63	0.58
2-oxovaleric acid	0.01*	0.57	0.35	0.89
3-hydroxybutyric acid	0.03*	0.44	0.52	0.81
Ketoisovaleric acid	0.002**	0.05	0.14	0.52
Hypotaurine	0.07	0.04*	0.57	0.52
Inosine	0.01*	0.01*	0.35	0.23
Ornithine	0.01*	0.21	0.35	0.65
Proline	0.68	0.04*	0.92	0.52
Uric acid	0.36	0.002**	0.74	0.15
Xanthine	0.27	0.01*	0.71	0.23

FDR = False Discovery Rate, BH = Benjamini-Hochberg, TCA = Tricarboxylic acid, / = ratio, *: < 0.05, **: < 0.01, ***: < 0.001

Table S4–b: False Discovery Rate Analysis (FDR) on the 50 significant metabolites obtained following a 12-week High–Intensity Interval Training (HIIT) or Moderate–Intensity Continuous Training (MICT) in obese older adults.

Metabolites	ANOVA		FDR (BH)	
	Time effect	Time×Training effect	Time effect	Time×Training effect
Fat metabolism				
Acetyl carnitine	0.02*	0.71	0.49	0.94
Arachidonic acid	0.02*	0.78	0.52	0.96
Butanoic acid	0.03*	0.84	0.52	0.97
Carnitine C18:0	0.04*	0.55	0.56	0.88
Ceramide (18:1/22:0)	0.94	0.02*	0.98	0.71
Ceramide (18:1/24:0)	0.39	0.03*	0.74	0.49
DG (18:1/18:3)	0.86	0.0004***	0.96	0.14
DG (20:4/18:2)	0.04*	0.67	0.56	0.94
Isobutyric acid	0.007**	0.15	0.35	0.57
Linoleic acid	0.03*	0.66	0.69	0.52
Margaric acid	0.001**	0.28	0.09	0.72
Pantothenic acid	0.09	0.003**	0.57	0.15
PCae (15:0)	0.18	0.01*	0.68	0.25
PCae (16:0)	0.19	0.02*	0.69	0.41
PCae (20:2)	0.75	0.03*	0.93	0.49
PCae (22:1)	0.29	0.03*	0.72	0.80
PCae (22:4)	0.92	0.04*	0.52	0.52
PEaa (36:1)	0.67	0.04*	0.92	0.51
PEaa (38:6)	0.74	0.02*	0.93	0.41
PEee (19:1)	0.02*	0.03*	0.49	0.49
TG (12:0/12:0/16:1)	0.04*	0.48	0.56	0.82
TG (12:0/14:0/16:0)	0.02*	0.24	0.49	0.70
TG (14:0/16:0/16:0)	0.04*	0.74	0.56	0.94
TG (14:0/16:2/16:2)	0.03	0.81	0.52	0.97
TG (16:1/18:1/18:0)	0.35	0.003**	0.15	0.57
TG (16:1/18:3/18:2)	0.09	0.004**	0.74	0.15
TG (16:1/18:3/20:4)	0.96	0.02*	0.98	0.41
TG (16:2/18:2/18:2)	0.04*	0.002**	0.56	0.15
Undecanoic acid	0.06*	0.001**	0.57	0.15

FDR = False Discovery Rate, BH = Benjamini–Hochberg, DG = Diglyceride; PCae = acyl–alkyl–phosphatidylcholine; PEaa = alkyl acyl–phosphatidylethanolamine; PEee = ether–phosphatidylethanolamine; TG = Triglyceride *: < 0.05, **: < 0.01, ***: < 0.001

Table S5-a: False Discovery Rate Analysis (FDR) for each type of intervention alone on the 50 significant metabolites obtained following a 12-week High-Intensity Interval Training (HIIT) or Moderate-Intensity Continuous Training (MICT) in obese older adults.

Metabolites	ANOVA		FDR (BH)	
	HIIT effect	MICT effect	HIIT effect	MICT effect
TCA cycle				
2-oxoglutaric acid	0.01*	0.0007***	0.29	0.04*
3-methylhistidine	0.03*	0.06	0.94	0.14
Aspartic acid	0.004**	0.12	0.19	0.65
Fumaric acid	0.003**	0.09	0.17	0.59
Pyruvic acid and Oxaloacetic acid	0.14	0.09	0.58	0.59
Aspartate/Malate	0.003**	0.08	0.17	0.58
Carbohydrate metabolism				
Acetic acid	0.02*	0.72	0.42	0.72
Glyceric acid	< 0.0001***	0.19	0.003**	0.69
Ribitol	0.15	0.13	0.58	0.65
Xylitol	0.79	0.0003***	0.93	0.04*
Xylose	0.47	0.005**	0.72	0.14
Amino acid metabolism				
2-amino adipic acid	0.39	0.008**	0.66	0.17
2-hydroxybutyric acid	0.01*	0.38	0.38	0.56
2-oxovaleric acid	0.01*	0.29	0.29	0.82
3-hydroxybutyric acid	0.14	0.05	0.58	0.56
Ketoisovaleric acid	0.12	0.001**	0.55	0.04*
Hypotaurine	0.74	0.007**	0.89	0.14
Inosine	0.0008***	0.48	0.09	0.86
Ornithine	0.17	0.01**	0.59	0.19
Proline	0.41	0.06	0.58	0.56
Uric acid	0.25	0.002**	0.59	0.04*
Xanthine	0.54	0.005**	0.77	0.14

FDR = False Discovery Rate, BH = Benjamini-Hochberg, HIIT = High-Intensity Interval Training; MICT = Moderate-Intensity Continuous Training; TCA = Tricarboxylic acid, / = ratio, *: < 0.05, **: < 0.01, ***: < 0.001

Table S5–b: False Discovery Rate Analysis (FDR) for each type of intervention alone on the 50 significant metabolites obtained following a 12-week High–Intensity Interval Training (HIIT) or Moderate–Intensity Continuous Training (MICT) in obese older adults.

Metabolites	ANOVA		FDR (BH)	
	HIIT effect	MICT effect	HIIT effect	MICT effect
Fat metabolism				
Acetyl carnitine	0.03*	0.28	0.44	0.82
Arachidonic acid	0.08	0.12	0.53	0.65
Butanoic acid	0.09	0.15	0.53	0.65
Carnitine C18:0	0.04*	0.37	0.44	0.82
Ceramide (18:1/22:0)	0.10	0.06	0.65	0.56
Ceramide (18:1/24:0)	0.05	0.16	0.44	0.65
DG (18:1/18:3)	0.04*	0.001**	0.44	0.04
DG (20:4/18:2)	0.05	0.39	0.44	0.83
Isobutyric acid	0.70	0.002**	0.17	0.90
Linoleic acid	0.03	0.33	0.38	0.36
Margaric acid	0.03*	0.006	0.44	0.14
Pantothenic acid	0.71	0.0007***	0.88	0.04
PCae (15:0)	0.01*	0.15	0.29	0.65
PCae (16:0)	0.02*	0.22	0.29	0.74
PCae (20:2)	0.13	0.10	0.45	0.62
PCae (22:1)	0.04*	0.22	0.88	0.90
PCae (22:4)	0.25	0.06	0.45	0.56
PEaa (36:1)	0.12	0.12	0.55	0.65
PEaa (38:6)	0.10	0.07	0.55	0.58
PEee (19:1)	0.48	0.003**	0.73	0.10
TG (12:0/12:0/16:1)	0.18	0.08	0.59	0.59
TG (12:0/14:0/16:0)	0.17	0.03	0.59	0.49
TG(14:0/16:0/16:0)	0.12	0.14	0.55	0.65
TG (14:0/16:2/16:2)	0.09	0.15	0.59	0.65
TG (16:1/18:1/18:0)	0.33	0.003**	0.65	0.10
TG (16:1/18:3/18:2)	0.83	0.0009	0.44	0.04
TG (16:1/18:3/20:4)	0.16	0.05	0.94	0.55
TG (16:2/18:2/18:2)	0.98	0.0003***	0.98	0.04
Undecanoic acid	0.0008***	0.06	0.09	0.56

FDR = False Discovery Rate, BH = Benjamini–Hochberg, HIIT = High–Intensity Interval Training; MICT = Moderate–Intensity Continuous Training; DG = Diglyceride; PCae = acyl–alkyl–phosphatidylcholine; PEaa = alkyl acyl–phosphatidylethanolamine; PEee = ether–phosphatidylethanolamine; TG = Triglyceride *: < 0.05, **: < 0.01, ***: < 0.001

List of inclusion and exclusion criteria of the participants

To be included in this study, participants had to meet the following criteria: 1) age 60 and over; 2) obese (BMI between 30 and 40 kg.m⁻² or fat mass (%; DXA) equal or superior to 27% in men and 40% in women) or a waist circumference greater than 102 cm for men and 88 cm for women; 3) inactive (less than two hours of structured physical activity per week); 4) no involvement in a vigorous exercise program for at least 12 months; 5) able to follow the exercise training; 6) stable weight (± 5 kg) for 6 months; 7) non-smokers and moderate drinkers (max: 15 g/day of alcohol); 8) able to understand French or English; and 9) postmenopausal for women (*i.e.*, 12 consecutive months without menses). Exclusion criteria were the following: 1) presence of metal implant (pacemaker); 2) asthma requiring oral steroid treatment; 3) use of medication that could affect metabolism or cardiovascular function; 4) use of anticoagulants (only for participants undergoing biopsies). Participants with diagnosed but untreated neurological, cardiovascular or lung diseases, or cognitive disorders were also excluded.